Table 6.
iVasoD compared to placebo or usual care for ARDS
| Patient or population: adults with ARDS Settings: intensive care Intervention: iNO for all studies Comparison: placebo or usual care | ||||||
| Outcomes | Illustrative comparative risks (95% CI) | Relative effect (95% CI) | No. of participants (studies) | Quality of evidence (GRADE) | Comments | |
| Control risk | Intervention risk | |||||
| Placebo/Usual care | iVasoD | |||||
| Mortality (pooled) | 315 per 1000 | 346 per 1000 (296 to 406) |
RR 1.10 (0.94 to 1.29) |
1142 (nine studies) |
++-- LOW Due to serious risk of bias and serious indirectness |
Six out of nine studies compared iNO with usual care rather than placebo Highly variable dose and duration of iNO and inclusion criteria |
| Adverse event: renal dysfunction | 124 per 1000 | 191 per 1000 (142 to 258) |
RR 1.55 (1.15 to 2.09) |
919 (four studies) |
++-- LOW Due to serious risk of bias and serious indirectness |
Highly variable dose and duration of iNO and inclusion criteria Variable criteria used to define renal dysfunction |
ARDS, acute respiratory distress syndrome; iNO, iVasoD, inhaled nitric oxide; iVasoD, inhaled vasodilators.